Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

)RU5HJLVWUDWLRQ&DOO RU

Stem Cell 2011

The Two day Stem Cell Conclave and Exhibition 2011 in its second year will be the biggest Stem Cell Event that will bring the future of this dynamic Industry to life for Investors, Industry, Practitioners, Patients, Analysts and people from all walks of life

Stem Cell 2011

,QGLD6WHP&HOO 6WHP&HOO&RQFODYH ([KLELWLRQ

Stem Cell 2011

Stem Cell 2011

Venue: The Westin Hotel, Mumbai

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai

A brief on the India Stem Cell Conclave 2011 & India Stem Cell Exhibition 2011 and the India Stem Cell Investor Business Meet 2011 This will be the most defining year for the Stem Cell Industry in India, the long awaited formation of the National Apex Committee for Stem Cell Research and Therapy has been set up by the Union ministry of Health, paving the way for the committee to review all controversial and ethically sensitive stem cell research proposals" and "oversee, monitor and make policies on stem cell use in India."All institutions and investigators carrying out research on human stem cells will have to be registered with NAC-SCRT through an Institutional Committee for Stem Cell Research and Therapy (ICSCRT). All research studies and clinical trials will need prior approval of IC-SCRT and NAC-SCRT. All new stem lines will be created and all established cell lines from any source, imported or created in India, will also have to be registered with IC-SCRT and NAC-SCRT. The permissible areas of research include invitro studies on established cell lines from any type of stem cell – hES (Human Embryonic Stem cells), hEG (Human Embryonic Germ Cells), hSS ( Human Somatic Stem Cells) or foetal adult stem cells, provided they are registered with IC-SCRT. Many companies that we had approached last year for the India Stem Cell Conclave & Exhibition 2010, had clearly indicated to us that unless there was a clear indication from the government on what areas of stem cell research could be carried out and which areas you could not. There was no scope for these companies to actively invest or participate in the development of this industry. Now that the National Apex Committee for Stem Cell Research and Therapy has been set up, we can expect a huge traction in many companies looking at opportunities to be a part of the Stem Cell Industry and playing a vital role in the Development of this burgeoning Industry. India Stem Cell Conclave 2011 The Second Annual Event this year will be the biggest Stem Cell event in India and will cover the most cutting-edge content in stem cell research and commercial stem cell use. Industry experts across India and across the world will converge to share papers on their stem cell research, debate and discuss on how to overcome the challenges facing the Stem Cell industry in India and across the world, which can open new opportunities in the area of research, therapy and stem cell banking. Also this program could be a great opportunity for companies within India and across the world to forge new partnerships and also open doors for international companies to actively participate in this burgeoning Industry. India Stem Cell Exhibition 2011 In its second year this platform will be opened to people from all walks of life from across India to get in-depth information on Stem cell Storage and clinical treatments and also come face to face with the peopleInvestors behind the Stem Cell Industry. , this can also help many companies that want to enter the Indian market with real time feedback and Academics valuable insight, which can help in the decision making process of setting up a base in the India. This platform will also be opened for companies supporting research to showcase their technology that can help researchers find new insights into the potential of Stem Cells.

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai

Platinum Sponsor Lifecell International

Silver Sponsor Cytori Therapeutics, Inc

Exhibiting Sponsor

Global Hospitals

Unistem Biosciences Pvt. Ltd

Endorsing Partner Beckman Coulter India

Invitrogen BioServices India

Lonza India

Supporting Partners

Event Organiser

Event Partner

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai

What you will be taking back from this conclave: Learn Latest Trends In Adult Stem Cell Research, Clinic Trials And Therapy For Diabetes I II III Understand The Use Of Cardiac Stem Cell For The Regeneration Of Heart Muscle Tissues Learn Tissue Engineering: " Engineering Approaches To Regenerating Damaged Neural Tissue Learn Stem Cells And Regenerative Medicine For Joint Repair Learn Latest Trends In Regeneration Of Degenerated Intervertebral Discs Using Stem Cells Understand Gene Correction In Human Embryonic And Induced Pluripotent Stem Cells: Promises And Challenges Ahead Understand How To Integrate Software Solutions In Analyzing Real Time-Lapse Of Live Stem Cell Behavior s Understand Current Situation And Future Outlook For The Cord Blood Bank Industr y In India Learn How To Access Various Options For Securing Investment For Stem Cell Companies Learn How To Build A Business Development Model For Stem Cells And Regenerative Medicine Learn What Are The Challenges And Opportunities Faced By Hospitals Physicians In Adopting And Providing Stem Cell Therapies

And

Learn How the Newly Formed N ational Apex Committee for Stem Cell Research and Therapy Approve And Evaluate Stem Cell Application And Stem Cell Therapy In India

Who Should Attend: CEO

CIO

CFO

Business Leaders

MD

CMO

Media

Pharmaceutical Companies

Scientists

Stem Cell Banks

Investors

Biotech Companies

Academics

Policy Makers

Goverment Institutions

Research Institutions

Researchers

Hospitals

NGO Doctors Surgeons

Equipment Providers

Business Development

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai AGENDA : Science Track 9:00am

Welcome And Keynote Address

Chief Guest: 9:30am

Clinical Experience of Adipose Derived Stem & Regenerative Medicine In 2011; A 38 Country Review And 3000 Patient Experience Speaker: Dr. John Fraser (Principal Scientist) - Cytori Therapeutics Inc.

10:15am

Stem Cell Research, Clinical Trials and Therapy In Neurodegenerative Disorder

Speaker: Dr. N. K. Venkataramana (Director) - Advanced Neuro-Science Institute and (Vice-chairman) BGS-Global Hospitals 11:00am

Morning Refreshment Break

11:30am

Autologous Vs Allogeneic Models For Stem Cell Transplant

Speaker: Dr. Soniya Nityanad (Head of hematology department) - Sanjay Gandhi Postgraduate Institute of Medical Sciences

12:15pm

Articular cartilage stem cells - suitable tools for cartilage repair?

Speaker: Dr. Charlie Archer (Professor) - Cardiff Institute of Tissue Engineering and Repair, School of Biosciences Cardiff University 1:00pm 2:30pm

Networking Lunch The Regeneration Of Degenerated Intervertebral Discs Using Stem Cells

Speaker: Dr.Helena Barreto Henriksson - The Lundberg Laboratory for Orthopaedic Research Sahlgrenska University Hospital, Sweden

3:15pm

The Use Of Stem Cells Derived From Cord Blood For Clinical Treatment

Speaker: Dr. Purvish Parikh (Managing Director India and Vice President USA) - AmeriCares India Foundation 4:00pm

Evening Refreshment Break

4:30pm

Use of pluripotent stem cells to study disease and develop therapies

Speaker: Dr. Paul J Verma (Senior Research Fellow & Senior Scientist) - Centre for Reproduction & Development at Monash Institute of Medical Research, Australia

5:15pm

Assessing Various Options For Securing Investment For Stem Cell Companies

Speaker: Mr. Nalin Kumar (Managing Director and Head of Merger & Acquisition and Equity Capital and Advisory) - Rabo Bank India

6:00pm Close of Day One

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai AGENDA : Industry Track 9:00am

Current Overview Of The Stem Cell Industry And The Opportunity For India To Play A Active Role In The Development Of This Industry Speaker: Mr. Mayur Abhaya (President & Executive Director) - LifeCell International 9:30am

How Will The International Patent Policies Impact The Development Of Stem Cell Research in India?

Speaker: Dr.Milind Antani (Head Pharma & Life Sciences) - Nishith Desai Associates

10:15am

Why Are Majority Of The Pharma And Biotech Companies In India Still Not Actively Involved In Developing The Stem Cell Industry Speaker: Ms.Dipta Chaudhury (Programme Manager - South Asia and Middle East, Pharma and Biotech Practice) - Frost & Sullivan

11:00am

Morning Refreshment Break

11:30am

How will the Indian Government’s Initiative and policy Framework help strengthen Stem Cell research and Stem Cell therapy in India? Speaker: Dr. V.M. Katoch (SECRETARY DEPARTMENT OF HEALTH RESEARCH) & (DIRECTOR GENERAL) - Indian Council of Medical Research invited

12:15pm

Therapeutic and Research Potential of Human Stem Cells

Speaker: 1:00pm

Networking Lunch

2:30pm

How Will The National Apex Committee For Stem Cell Research And Therapy Approve And Evaluate Stem Cell Application And Stem Cell Therapy In India? Speaker: Dr. Alok Srivastava (Chairman) - National Apex Committee for Stem Cell Research and Therapy invited

3:15pm

What Are the Challenges And Opportunities Faced By Hospitals And Physicians In Adopting And Providing Stem Cell Therapies? Speaker: Dr. Uma Nambiar, (Zonal Director Mumbai) - Fortis Healthcare Ltd & (CEO) - S L Raheja (A Fortis Associate) Hospital

4:00pm

Evening Refreshment Break

4:30pm

Transforming Stem Cell Research Into Truly Innovative Products Which Are Available To Physicians And Patients

Speaker: Dr. Satish Totey - Stem Cell Research Consultant

5:15pm

Panel Discussion: What Does The Future Hold For Stem Cell Research And Therapy For India

Moderator: Mr. David Oxley (Vice President Emerging Market Sales) - Cytori Therapeutics Panelist:

6:00pm: Close of Day 2 For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai

Mr. Mayur Abhaya (President & Executive Director) - LifeCell International Mayur joined LifeCell International in August 2008 taking charge as President & Executive Director, and has been instrumental in the transformation of the company from a single service to a multi-service provider with the introduction of new services such as umbilical cord tissue banking, newborn genetic testing, menstrual blood banking and also manufacturing outsourcing services in stem cell industry. Further under his leadership the company is continuing to invest significantly into research and development programs in order to bring novel cell-based therapies into the country. Prior to joining LifeCell he was with Shasun Chemicals – one of India’s prime pharmaceutical contract manufacturing company supplying to greater than 100 countries across the world. Over the 7 years at Shasun he has severed in various capacities such as Head - Intellectual Property & Licensing, and Head – Generics. He was part of the core committee which was responsible for the acquisition of Rhodia Pharmaceuticals, UK, and also championed information technology initiatives such as SAP ERP implementation, and Information Security and Management accreditations. Mayur has graduated from Anna University with a Bachelors Degree in Industrial Biotechnology, and subsequently pursued his Masters in Science in Biotechnology Management from Northwestern University, USA. Mayur is also a certified Six Sigma Black Belt professional.

Dr. Purvish Parikh (Managing Director India and Vice President USA) - AmeriCares India Foundation Dr Purvish M Parikh is a medical oncologist and hematologist who has been a pioneer in stem cell therapy in India. He is responsible for the first umbilical cord blood transplant as well as the first haploidentical transplant in India. He continued to lead several innovations while professor and head of medical oncology at Tata Memorial Hospital, Mumbai. Currently Dr Parikh is on a number of government committees, is Convener of Indian Cooperative Oncology Network, President of Indian Society of Medical and Pediatric Oncology, International Editor for JCO, USA, editor in chief of IJC and managing director of AmeriCares India Foundation. Previously Dr Parikh was distinguished visiting fellow at Harvard International, Boston and Oxford University, Oxford. He has also undergone extensive training at Royal Marsden Hospital, London; Memorial Sloan Kettering Cancer Center, NY and Johns Hopkins Hospital, Baltimore.

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai Dr.Helena Barreto Henriksson - The Lundberg Laboratory for Orthopaedic Research Sahlgrenska University Hospital Special interest in strategies for regeneration of degenerated intervertebral discs using stem cell therapy. Also working with normal regeneration of the intervertebral disc by studying progenitor cells at a genetic and protein level in animal models and human..

Dr Paul J Verma (Senior Research Fellow & Senior Scienst) - Centre for Reproducon & Development at Monash Instute of Medical Research. Dr Paul Verma obtained his PhD at Adelaide University and subsequently joined BresaGen Ltd, Adelaide in 1995, working on transgenesis and nuclear transfer aimed at developing pigs with organs suitable for xenotransplantation. He later joined the Luminis-BresaGen Cell Therapy Program, where he established a research program on cell reprogramming aimed at providing alternates to therapeutic cloning. Dr Verma moved to Melbourne in 2001 and to continue his research into reprogramming somatic cells, isolation and characterization of embryonic and adult stem cells as a Senior Research Fellow at MIMR. His overarching research aim is to produce autologous (patient-specific) stem cells, using cell reprogramming techniques such as somatic cell nuclear transfer and iPS cells technology, that are clinically relevant and transplantable into humans. He has published many scientific papers and edited a book on transgenesis, cloning and stem cells. He is principal inventor on eight granted and provisional patents in the field of cell reprogramming and stem cells. He has recently been appointed to serve on the NHMRC Cellular Therapies Advisory Committee and is a Visiting Professor at the National Centre for Biological Science, Bangalore, India. Dr. Uma Nambiar, (Zonal Director Mumbai) - Fortis Healthcare Ltd & (CEO) - S L Raheja (A Fortis Associate) Hospital Dr. Uma Nambiar is the Director for the Mumbai Zone for Fortis Healthcare Ltd. and CEO of S. L. Raheja (Fortis Associate) Hospital, Mumbai since March 2009. She is a Qualified Neurosurgeon and Healthcare Administrator. She has completed MBBS and MS (general surgery) from Armed Force Medical College, Pune & M.Ch in Neurosurgery from Sree Chitra Tirunal Institute for Medical Sciences and Technology from Trivandrum. She has completed MBA in Healthcare Administration from FMS (Faculty of Management Studies), Delhi. She is also a Qualified internal auditor for ISO and Lead Assessor for NABH. She has wide experience in ranging teaching experience in Neurosurgery, Hospital administration, Quality in Healthcare and Clinical Engineering. She is Visiting (adjunct) Faculty with IHMR Jaipur, IHMR Bangalore, MGM university Mumbai and Sree Chitra Tirunal Institute for Medical Sciences & Technology.

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai Mr. Nalin Kumar (Managing Director and Head of Merger & Acquisition and Equity Capital and Advisory) Rabo Bank India Nalin started his banking career with HSBC in 1993. Thereafter he moved into investment banking with J.P. Morgan Chase. He had worked in New York, Singapore and Hong Kong offices of J.P. Morgan Chase initially supporting the Project, Structured Finance and Restructuring Groups in Asia, and subsequently as a key member of the Asian M&A effort working on several landmark transactions across industry verticals in key Asian markets. He joined DSP Merrill Lynch in their Indian operation in the year 2001. Here he led important M&A and Capital Market transactions across sectors. Prior to Rabo India he was with JM Morgan Stanley, where he was working since 2005. At JM, he lead the Financial Sponsors Group and worked across sectors. Nalin is a MBA from the Indian Institute of Management (IIM), Calcutta and holds a Bachelors degree in Chemical Engineering from Indian Institute of Technology (IIT), Kharagpur.

Dr. Satish Totey (Co-Founder, President & CEO) - Advanced Neuro-Science Allies Pvt. Ltd

Dr. Satish Totey is a reputed stem cell scientist in the country with more than 30 years of experience in stem cell research, transgenic animals, gene knockout, mammalian gene expression, developmental biology. Out of his total 30 years of research and corporate experience he spent around 20 years at National research Institute and his research interest was molecular signalling. He is a pioneer in transgenic research in India and developed several transgenic lines for several human diseases and gene knockout mice for functional genomic studies and gene and protein expression. He has a vast experience in both human embryonic and adult stem cells and developed large scale clinical scale up of mesenchymal stem cells. He was first to initiate stem cell clinical trial in the country. He has published several scientific papers in the International journals. He is a member of editorial board of several International and national journals and member of task force committee. Dr.Milind Antani (Head Pharma & Life Sciences) - Nishith Desai Associates Dr. Milind Antani heads the Pharma and Life Sciences Practice at the multi-skilled, research-based international law firm, Nishith Desai Associates (www.nishithdesai.com) with offices in Mumbai, Silicon Valley, Bangalore and Singapore. Dr. Antani represents clients in matters including corporate mergers and acquisitions, regulatory and transactional matters, intellectual property prosecution and litigation, joint ventures and formation of new companies. Dr. Antani practiced as an ENT surgeon in Gujarat for 14 years prior to joining Nishith Desai Associates. Dr. Antani received a Doctorate from Baroda Medical College, Vadodara, Gujarat and a Bachelor of Law from Sardar Patel University, Vallabh-Vidyanagar, Gujarat. His practice areas include Pharmaceutical, Life Sciences, Healthcare, Intellectual Property and Medical Devices. Dr. Antani has authored and co-authored many articles, publications related to the pharma industry including a book on Legal and Tax Framework: Indian Pharmaceutical Industry, published by CCH, 2008. He has been invited by national and international forums to speak at various conferences and seminars on the subjects of pharma, biotech, IP, clinical trials etc. Dr Antani has been a visiting faculty at NMIMS, IIPS, Bombay College of Pharmacy, SIES College, PG dept of Biotechnology. Dr Antani is also the member of FICCI, National Pharmaceutical Committee, FICCI-Gujarat Health care committee and the Committee of Telemedicine Society of India.

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai Dr. John Fraser (Principal Scientist) - Cytori Therapeutics Inc Dr Fraser is Principal Scientist at Cytori Therapeutics Inc, a San Diego-based biotechnology company engaged in commercialization of adult stem and regenerative cells obtained from human adipose tissue. He has more than 25 years of experience working with adult stem cells in both academia and industry. Prior to joining StemSource (a company that has evolved into Cytori), Dr Fraser was an Adjunct Associate Professor in the Division of Hematology-Oncology within the Department of Medicine at the David Geffen School of Medicine at UCLA and a member of the Jonsson Comprehensive Cancer Center. During a 12 year career at UCLA Dr Fraser spent three years as the Co-Director of the UCLA Bone Marrow Transplant Laboratory, the facility responsible for processing and cryopreservation of all bone marrow and peripheral blood stem cells used in marrow transplants at UCLA. He also founded and, from 1995 until he left to join StemSource, was the Director and Principal Investigator of, the UCLA Umbilical Cord Blood Bank, a NIH-funded allogeneic cord blood stem cell bank. In addition, Dr Fraser was a member of one of UCLA’s two Medical Institutional Review Boards for seven years and served as Vice Chair of the Board for two years. He has served on five NIH panels reviewing stem cell-related research proposals Dr Fraser has a PhD from the University of Otago in New Zealand and a Bachelor of Science degree (Biochemistry and Physiology) from Victoria University of Wellington. He has published more than 40 peer-reviewed papers, has several patents issued in the USA, and has been awarded more than $12 million in research contract and grant funding from the National Institutes of Health in both academia and industry.

Ms. Dipta Chaudhury (Programme Manager - South Asia and Middle East, Pharma and Biotech Practice) Frost & Sullivan Dipta Chaudhury, MBA is a Program Manager for Frost & Sullivan-South Asia and Middle East Division. She has over eight years experience in corporate strategic and product development during which she acquired an expertise in the global pharma industry with an emphasis on India. Her background covers a broad range of sectors, from pharma research and development to finished product marketing, pipeline identification, strategic and business plan development, domestic and international sales and marketing and financial advising. Prior to Frost & Sullivan, Ms. Chaudhary worked for Torrent Pharmaceuticals' Indian, EU and US operations in sales and marketing, strategic business development, and R&D. Her background also includes domestic and international experience in the API business market with Zydus Cadila and in the Healthcare Business Advisory division of YES Bank in Mumbai.

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai Mr. David Oxley (Vice President Emerging Market Sales) - Cytori Therapeutics Inc David C. Oxley serves as Vice President of Emerging Markets Sales for Cytori Therapeutics (NASDAQ: “CYTX”), a public company engaged in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. Mr. Oxley’s remit includes establishing Cytori subsidiaries and commercial sales and distribution activities across Latin America, Africa, India, Thailand, Malaysia, Australia and New Zealand. Prior to accepting this new role in support of Cytori’s strategic growth plans, Mr. Oxley served as Vice President of Marketing. In a marketing capacity, Mr. Oxley developed and directed an operational marketing team responsible for tactical marketing and sales support functions for Cytori’s global sales organization, including the E.U, Japan, and the U.S. Prior to his current remit, Mr. Oxley served as Executive Vice President of World Wide Sales & Marketing for the Pointof-Care Division for Trinity iotech, plc (NASDAQ: “TRIB”), a public company specializing in the development, manufacture and marketing of clinical diagnostic products. Mr. Oxley’s remit included global responsibility for point-ofcare market segments in addition to the development of an over-the-counter consumer market strategic business unit. In addition to his sales and marketing role, Mr. Oxley served as head of U.S. investor relations. Prior to his tenure at Trinity Biotech, Mr. Oxley served a combined sixteen years in leadership positions in the IVD market, including head of government relations for a medical device company, health care banking for a national bank, health care advocacy and lobbying for a Washington, D.C. law firm, and health-care policy work for a member of the United States House of Representatives. In concert with his corporate experiences, Mr. Oxley served in professional and not-for-profit entities including delegate of the Private Sector Delegation to the Board of the Global Fund to Fight HIV TB & Malaria, outside director on the Board of the Children’s AIDS Fund and past member of the National Association of Securities Dealers, United States Army National Guard, and United States Air Force Reserve.

Dr. Charlie Archer (Professor) - Cardiff Institute of Tissue Engineering and Repair, School of Biosciences Cardiff University Charles W. Archer is Professor of Reparative Biology and Tissue Engineering at the School of Biosciences, Cardiff University and the Cardiff Institute of Tissue Engineering and Repair (CITER). He also is former Head of the Connective Tissue Biology Laboratories within Biosciences, one of the 6 themed research groups within the school. Having graduated at the University College of Swansea in Zoology, remained there to pursue a PhD in the effects of pulsed magnetic fields on fracture healing. He then carried out post-doctoral work at the Middlesex Hospital Medical School on cartilage morphogenesis under Prof. Lewis Wolpert before moving to the Institute of Orthopaedics, University College, London as Lecturer and then Senior Lecturer in Cell Biology before moving to Cardiff as Professor of Anatomy. He also has a company 'Progenteq' (Fusion IP) that is committed to using endogenous articular cartilage stem cells for focal and larger lesion repair.

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai About India Stem Cell Conclave 2010 and India Stem Cell Exhibion 2010 Asia Knowledge Associates, conducted a comprehensive 2 day program Called India Stem Cell Conclave 2010 and India Stem Cell Exhibion 2010 on the 23rd and 24th October 2010 at the Hya Regency Hotel Mumbai. India Stem Cell Conclave 2010 offered a two day program of the most cung-edge content in commercial stem cell use. Industry experts converged to debate and discuss how to overcome the challenges facing the Stem Cell industry in India, which can open opportunies for companies to invest and be a part of this burgeoning Industry. We also hosted India’s first premier Stem Cell Exhibion; the expo was concurrently running with the conclave and was open for public from all walks of life to parcipate. Over 200 people aended the Exhibion and for many this was a first me opportunity to get in-depth informaon on Stem cell Storage and clinical treatments and also come face to face with the people behind the Stem Cell Industry. The panel of Eminent Speakers for the India Stem Cell Conclave 2010: Dr. V.M. Katoch (SECRETARY DEPARTMENT OF HEALTH RESEARCH) & (DIRECTOR GENERAL) - Indian Council of Medical Research, Ms. Lisa Ray Actress, Model, Writer and Stem Cell Advocate, Dr. Irene Marni (Co-founder and Scienfic Director) - Nanog Internaonal Italy Mr. Arnoud Van Tulder (Group CEO) - Cryo-Save Netherlands, Dr. Praful Pawar (CEO) - Apollo Hospitals, Dr. Alok Sharma Sion Hospital, Dr. Sash Totey (Co-Founder, President & CEO) - Advanced Neuro-Science Allies Pvt. Ltd, Dr. Vasantha Muthuswamy (Senior Deputy Director General (Retd.)- Indian Council of Medical Research Press Coverage: http://www.dnaindia.com/entertainment/report_i-am-only-here-because-of-stem-cells-lisaray_1457242 http://www.hindustantimes.com/Awareness-is-biggest-challenge-for-stem-cell-therapyDoctors/Article1-617130.aspx www.business-standard.com/india/news/birthingnext-big.../413878/ http://topnews.ae/content/24585-unlawful-stem-cell-practices-concern-icmr-head http://timesofindia.indiatimes.com/entertainment/bollywood/news-interviews/Lisa-Rays-on-aglobal-mission/articleshow/6758833.cms http://ibnlive.in.com/news/lisa-promotes-stem-cell-technology-in-india/133644-1993.html?from=tn For more coverage of the India Stem Cell Conclave and Exhibion 2010 please visit www.stemcellconclave.com For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com

Asia Stem Cell 2011 Knowledge Date: 2nd & 3rd July, 2011

Venue: The Westin Hotel, Mumbai

Delegate Registration Form Completed contracts can be e-mailed or Faxed to

Delegate Information

Email: [email protected] Fax: 022 - 6675 7806 Please make cheques / DDs payable in favour of: "Goldman Communications" and send to: B-704,Kanara Business Center Behind Everest Gardens Ghatkopar (East) Mumbai 400 077 India Tel: +91 22 6717 9500

Name: Designation: Direct Phone / Extn: Email: Name: Designation: Direct Phone / Extn: Email: Name: Designation: Direct Phone / Extn: Email: For more delegates, please send delegate information on another page

Delegate Package 1 Single Delegate INR 14,900 + 10.3% Service Tax 2 Two Delegates INR 27,800 + 10.3% Service Tax 3 Three Delegates INR 37,500 + 10.3% Service Tax Speacial Room Package at Wesitn Hotel Mumbai

Single Occupancy INR 6650 per night + 10% Government Luxury Tax Double Occupancy INR 7150 per night + Government Luxury Tax

Company: Address:

Authorized by / Billing Information:

Your Signature & Company Seal This booking is invalid without a signature. Date: Delegate fees is to reach us within 7 days of contract date

Signatory must be authorized to sign on behalf of contracting organization

Name: Designation: Phone: Fax: Email:

Terms & Conditions: 1. Fees are inclusive of programmes materials and refreshments and the event is non-residential 2. Payment Terms: Following completion and return of the registration form, full payment is required within 5 days from receipt of invoice. PLEASE NOTE: Payment must be received prior to the conference date. 3. Cancellation /Substitution: Provided the total fee has been paid, substitutions at no extra charge are allowed. Cancellations must be received in writing by mail or fax Two (2) weeks before the conference is to be held in order to obtain a full credit for any future Goldman Communications conference. Thereafter, the full conference fee is payable and is non refundable. The service charge is completely non-refundable and non-creditable. Nonpayment or non-attendance does not constitute cancellation. If, for any reason, The Organisers Asia Knowledge Associates along with the event partners Goldman Communications decides to cancel or postpone this conference, The Organisers Asia Knowledge Associates along with the event partners Goldman Communications is not responsible for covering airfare, hotel, or other travel costs incurred by clients. The conference fee will not be refunded, but can be credited to a future conference. Event programme content is subject to change without notice.4. Copyright etc: All intellectual property rights in all materials produced or distributed by The Organisers Asia Knowledge Associates along with the event partners Goldman Communications in connection with this event is expressly reserved and any unauthorized duplication, publication or distribution is prohibited.5. Governing law: This Agreement shall be governed and construed in accordance with the law of India and the parties submit to the exclusive jurisdiction of the Indian Courts in Mumbai.

For more details & registrations please contact Tel. +91 22 67179500 / Mob.91 9819995311 or visit us at www.goldmancommunications.com